Kymera Therapeutics KYMR is leveraging targeted protein degradation (TPD), a next-generation small-molecule therapeutic modality that harnesses the body's natural cellular recycling system to selectively eliminate disease-causing proteins.
The company is developing lead candidate KT-621, an oral STAT6 degrader, for inflammatory diseases such as atopic dermatitis (AD) and asthma.
The company recently completed enrollment in its phase IIb BROADEN2 study on KT-621 for the treatment of moderate-to-severe AD, about six months ahead of schedule. This means investors may see pivotal efficacy data by the end of 2026 instead of waiting until 2027, pulling forward a major catalyst.
Pending regulatory discussions, the company plans to begin phase III studies in AD by mid-2027.
In January 2026, Kymera expanded the BROADEN2 study to include adolescents alongside adults.
Kymera had earlier reported positive data from the phase Ib BroADen study of KT-621 in AD. The data was presented in a late-breaking oral session at the American Academy of Dermatology Annual Meeting. The findings demonstrated robust STAT6 degradation, reductions in type 2 inflammatory biomarkers, encouraging clinical activity, and a favorable safety profile, supporting STAT6 degradation as a novel oral therapeutic approach for type 2 inflammatory diseases.
Positive data highlight the candidate’s potential as an effective oral alternative to injectable biologics.
KT-621 is also being investigated in the ongoing phase IIb BREADTH trial in moderate-to-severe eosinophilic asthma, with data anticipated in late 2027.
The candidate has received Fast Track designation from the FDA for the treatment of moderate-to-severe AD and eosinophilic asthma.
The successful development of the candidate will be a significant boost for the company.
Competition for KYMR’s in Protein Degrader Therapies
Arvinas ARVN is a clinical-stage biotechnology company pioneering PROTAC (PROteolysis TArgeting Chimera) protein degradation therapies.
ARVN, in partnership with Pfizer, developed Veppanu (vepdegestrant), the first FDA-approved PROTAC therapy, for adults with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy.
Arvinas is advancing a diversified pipeline of investigational therapies, including ARV-102 for neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers such as pancreatic and colorectal cancer, ARV-393 for relapsed/refractory non-Hodgkin lymphoma, ARV-027 for spinal-bulbar muscular atrophy (Kennedy's disease), and vepdegestrant for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer.
Nurix Therapeutics NRIX, a clinical-stage biopharmaceutical company, is also developing targeted protein degradation therapies for cancer and autoimmune diseases. Nurix's clinical pipeline includes bexobrutideg, a BTK degrader being co-developed with Roche for oncology and autoimmune indications; NX-1607, a CBL-B inhibitor for cancer; and an IRAK4 degrader partnered with Gilead for autoimmune diseases.
NRIX is also advancing a portfolio of preclinical protein degraders and degrader-antibody conjugates, supported by strategic collaborations with Roche, Gilead, Sanofi and Pfizer.
KYMR’s Price, Valuation and Estimates
Shares of the company have gained 41.9% year to date compared with the industry’s growth of 2%.
Image Source: Zacks Investment Research
Going by the price/book ratio, KYMR’s shares currently trade at 5.90X, higher than its mean of 3.57X and the industry’s 3.49X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 loss per share has narrowed to $3.28 from $3.30 over the past 60 days, while that for 2027 loss has widened to $4.23 from $4.19 in the same time frame.
Image Source: Zacks Investment Research
KYMR currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.